Intravascular Lithotripsy (IVL) Market Size & Share 2026-2035

Intravascular Lithotripsy (IVL) Market Trends

Multi-Modality Technology Innovation is Fragmenting the IVL Platform Landscape

The IVL industry originated as a single technology category dominated by electrohydraulic shockwave delivery, as commercialized by Shockwave Medical. From 2023 onward, the technology landscape has fragmented into four distinct energy delivery modalities: electrohydraulic, laser based, mechanical contact, and hydraulic, each offering differentiated performance characteristics across vessel size, calcification depth, and anatomical complexity. The underlying clinical driver is the recognition that calcified lesion morphology varies significantly by vessel bed, patient age, and cardiometabolic history. Lesions with predominantly superficial calcification respond well to current balloon based electrohydraulic systems, but deep medial and nodular calcifications, disproportionately prevalent in elderly and diabetic patients, may require different energy profiles for adequate fracture and vessel compliance restoration.

Boston Scientific's Bolt IVL system, acquired in January 2025 and FDA cleared for above the knee peripheral arterial disease in March 2025, employs laser generated acoustic pressure waves for more uniform circumferential energy delivery inside a balloon catheter. FastWave Medical's dual platform approach, the Artero electric IVL system for peripheral indications and the Sola laser IVL system for coronary indications, completed first in human procedures in 2024 and June 2025, respectively; the Artero system reported 100% procedural success with no adverse events at 30 days in its first in human peripheral study.

Cagent Vascular's Serranator Sonic IVL platform combines serration remodeling therapy with a SONIC lithotripsy generator, a dual modality design targeting calcification in femoropopliteal and infrapopliteal arteries, with first in human REMODEL I cases completed in 2025 alongside a USD 41 million Series D financing round. Supply chain leads and clinical program directors we interviewed across interventional cardiology programs at tertiary referral centers in the US and Europe indicated that more than 55% of physicians in active IVL programs were actively evaluating next generation platform options by early 2026, a materially higher proportion than 18 months earlier, when Shockwave remained the de facto clinical default across most institutional settings.

Clinical Application Expansion into Complex and Peripheral Indications

IVL's commercial trajectory was initially shaped by coronary artery disease, specifically the need for vessel preparation in heavily calcified de novo coronary stenoses prior to stenting. The FDA granted Pre-Market Approval for this indication in February 2021, following the successful completion of DISRUPT CAD III. However, the peripheral application was established earlier: Shockwave's peripheral IVL system received FDA clearance in 2016, and the DISRUPT PAD III randomized trial, the largest randomized study of peripheral IVL in severely calcified peripheral lesions, has generated clinical evidence out to 24 month follow up across femoropopliteal anatomies. The JACC: Cardiovascular Interventions published real world data from the REPLICA EPIC18 study demonstrating IVL feasibility and safety in ACS patients, with procedural success achieved in 89.1% of 376 consecutive patients treated at 18 centers in Spain.

The more consequential shift is the move into below the knee (BTK) indications, where calcification patterns are particularly complex and conventional angioplasty carries elevated failure and restenosis rates. Shockwave launched the Javelin Peripheral IVL Catheter in the US in March 2025, a forward deployed, non balloon-based platform designed to modify calcium and cross extremely narrowed vessels, reporting a major adverse event rate of 1.1% at 30 days and a technical acute procedural success rate of 99%. Boston Scientific has a BTK program in active clinical evaluation as part of its broader Bolt IVL development roadmap, and Cagent Vascular's REMODEL II pivotal trial encompasses infrapopliteal anatomy. Each of these programs addresses an unmet need population that is substantially larger than the pivotal coronary IVL opportunity from which the market originated.

Consolidation and New Entry are Simultaneously Reshaping Competitive Structure

The intravascular lithotripsy market is experiencing two simultaneous structural forces that are, in combination, redefining its competitive topology. On one side, major medtech incumbents are acquiring IVL capabilities through M&A: Johnson and Johnson completed its USD 13.3 billion acquisition of Shockwave Medical in 2024; Boston Scientific acquired Bolt Medical in January 2025 for up to approximately USD 664 million in upfront cash and milestone payments; and Stryker entered the market through the acquisition of Amplitude Vascular Systems and its Pulse IVL platform, completed in 2025 following AVS's USD 36 million financing in January of that year. On the other side, early-stage venture backed companies including FastWave Medical (over USD 40 million raised), Cagent Vascular (USD 41 million Series D), and Elixir Medical are advancing independent IVL platforms through clinical development, targeting specific niches in coronary and peripheral indications that existing commercial systems do not fully address.

The data indicates that new entrants are concentrating on laser-based delivery, dual modality approaches, and coronary indications currently dominated exclusively by the Shockwave/J&J platform. Abbott's entry through the TECTONIC CAD IVL IDE study, a 335 patient, 47 site US pivotal trial initiated in March 2025, and Boston Scientific's FRACTURE coronary IDE trial, commencing US enrollment in July 2025, confirm that both platform leaders and new entrants regard the coronary market as the primary competitive battleground. The second order effect of this competitive entry is a likely acceleration of institutional contract negotiations, as hospital systems gain leverage from the availability of multiple cleared or soon to be cleared IVL options.

Intravascular Lithotripsy (IVL) Market Analysis

By Product Type

Intravascular Lithotripsy Catheters and Balloons

Intravascular lithotripsy catheters and balloons represent the dominant product segment, accounting for 82.84% of intravascular lithotripsy market revenues in 2025, equivalent to approximately USD 790.6 million. The catheter and balloon segment's structural primacy reflects the consumable economics of IVL deployment: each procedure requires a new catheter, while generators function as capital equipment retained across a much larger number of patient encounters. At the segment level, the Shockwave C2 Coronary IVL Catheter and the Shockwave M5+ Peripheral IVL Catheter represent the commercially dominant product lines, supported by a comprehensive body of clinical evidence from the DISRUPT CAD I through IV and DISRUPT PAD III trial programs. The Shockwave C2+ and C2 catheters are designed for a broad range of calcified coronary morphologies, while the M5+ addresses above the knee peripheral lesions and the L6 and E8 extend coverage to larger and more complex vessel anatomies, respectively.

The Shockwave Javelin Peripheral IVL Catheter, launched in the US in March 2025, represents the first forward deployed IVL platform designed for treating subtotal occlusions in extremely narrowed peripheral vessels, extending the applicable anatomy beyond conventional balloon based catheter reach and reporting a 99% technical acute procedural success rate with a 1.1% major adverse event rate at 30 days. On the competitive side, Boston Scientific's Bolt IVL catheter, FDA cleared March 2025 for above the knee peripheral indications following the RESTORE ATK trial across 97 subjects, and the FastWave Artero electric IVL system are adding to the catheter level competitive field, further supporting catheter segment volume growth through procedural category expansion. The combined effect of new catheter launches, broadening anatomical indications, and entry of competitive platforms is expected to sustain catheter and balloon segment dominance throughout the forecast period, even as per unit pricing experiences moderate compression from multi-vendor competition in the peripheral sub segment.

IVL Generators and Consoles

IVL generators and consoles represent 12.83% of total intravascular lithotripsy market value in 2025, approximately USD 122.4 million, reflecting the installed base dynamics of capital equipment procurement within hospital cardiology and vascular surgery departments. Generator revenues are influenced by hospital purchasing cycles, capital budget approval timelines, and the staggered rollout of IVL programs in newer geographic markets. The Shockwave generator platform serves as the operational backbone for the full Shockwave IVL catheter portfolio across coronary and peripheral indications, and its wide installation across US, European, and select Asia Pacific catheterization laboratories represents a significant commercial infrastructure advantage. As multi vendor platform availability increases, the generator segment is expected to grow modestly in absolute terms but decline as a proportion of total IVL market revenue, with catheter volume growth outpacing capital equipment placements over the forecast period. The entry of Boston Scientific's Bolt IVL generator system and future coronary platforms from Abbott and FastWave will introduce additional generator procurements at the institutional level, supporting moderate absolute growth in this sub segment through the early to mid forecast years.

Accessories and Connector Cables

Accessories and connector cables account for 4.33% of market value in 2025, approximately USD 41.3 million, representing a stable ancillary revenue stream tied directly to catheter utilization rates and generator installed base size. This sub segment includes procedure specific consumables, interface cables, and supporting hardware components required for IVL system operation. Growth in this sub segment is closely correlated with total IVL procedure volume growth, rather than with independent technology innovation or commercial dynamics, making it a reliable but lower growth contributor to the overall market revenue profile over the 2026 to 2035 forecast period.

By Application

Coronary Artery Disease

Coronary artery disease is the primary application, accounting for 60.53% of IVL market revenue in 2025, approximately USD 577.9 million. The CAD segment's leadership reflects the earlier commercial maturity of coronary IVL, the higher per procedure device utilization within PCI workflows, and the concentration of the installed generator base in cardiac catheterization laboratories across North America and Europe. The ischemic heart disease burden was estimated at 254.3 million prevalent cases globally in 2021, with calcified lesions present in approximately 25 to 50% of CAD patients undergoing PCI, a structurally large addressable population that continues to grow as the global population ages. Adoption in Germany illustrates the reimbursement driven growth dynamic: a peer reviewed analysis of national hospital procedure data confirmed a consistent increase in the annual share of coronary IVL from 2019 to 2023, with IVL's procedural share eventually exceeding that of rotational atherectomy in Michigan (US), a transition directly associated with the 2021 introduction of IVL specific OPS Code 8-83d.6 and subsequent DRG uplifts in 2024.

Within the CAD sub segment, the Shockwave C2 and C2+ coronary IVL catheters represent the established commercial standard. The DISRUPT CAD Pooled analysis, currently the largest systematic assessment of coronary IVL outcomes based on individual patient data from DISRUPT CAD I through IV, provides a published safety and efficacy record that no competitive coronary system yet matches in scale or follow up duration. Abbott's TECTONIC CAD IVL IDE study, a 335 patient, 47 site US pivotal trial initiated in March 2025 with an estimated completion date of June 2028, and Boston Scientific's FRACTURE coronary IDE trial, commencing US enrollment in July 2025, are the two most advanced competitive programs targeting direct entry into Shockwave's highest volume revenue stream. The completion of these pivotal trials in the latter half of the forecast period is expected to intensify competitive pressure in the coronary sub segment, with meaningful commercial consequences for per unit pricing and institutional contract dynamics.

Peripheral Artery Disease

Peripheral artery disease accounts for 35.20% of intravascular lithotripsy market revenues in 2025, approximately USD 335.9 million, and represents the fastest growing application sub segment across the forecast period. The underlying demand is shaped by the high unmet clinical need in severely calcified peripheral stenoses, particularly in femoropopliteal and below the knee vessels where conventional balloon angioplasty carries elevated complication and restenosis rates. The DISRUPT PAD III randomized trial, the largest randomized study of peripheral IVL in severely calcified lesions, has generated outcomes data out to 24 months across femoropopliteal anatomies, establishing an evidence base that has supported guideline integration and broad physician adoption in high volume centers across North America and Europe.

The launch of the Shockwave Javelin Peripheral IVL Catheter in the US in March 2025 extended IVL applicability into sub total occlusions in extremely narrowed peripheral vessels, a segment previously inaccessible to balloon based platforms. Boston Scientific's Bolt IVL system, FDA cleared in March 2025 for above the knee peripheral arterial disease, and Cagent Vascular's Serranator Sonic IVL platform targeting femoropopliteal and infrapopliteal anatomies, are expanding the competitive field within peripheral IVL. Lepu Medical's IVL Balloon Dilatation Catheter System receiving ANVISA regulatory approval for the Brazilian market represents an important access milestone for peripheral IVL in Latin America. In our survey of 320 interventional cardiologists and vascular surgeons conducted across North America, Europe, and Asia Pacific in H2 2025, 68% identified peripheral IVL as the most significant procedural advance in PAD management over the preceding three years, a marked shift from approximately 41% in a comparable survey conducted in 2023, indicating rapid normalization of IVL as a standard peripheral vessel preparation option.

Other applications

Other vascular applications, encompassing renal artery interventions and certain complex structural presentations, account for 4.27% of market value in 2025, approximately USD 40.7 million. This sub segment represents an area of active clinical investigation as evidence accumulates for IVL utility beyond the established coronary and femoropopliteal indication set. The COSIRA II clinical trial, evaluating IVL for refractory angina and actively enrolling patients in the US, represents a potential expansion of the indication set that could contribute incremental revenue in the medium to long term. While this sub segment's current revenue contribution is limited, its strategic importance lies in the potential to extend the addressable patient population and procedural use cases available to IVL platform developers over the forecast horizon.

By Age Group

Geriatric (65 Years and Above)

The geriatric segment, comprising patients aged 65 years and over, represents the structural majority of the intravascular lithotripsy market, accounting for 70.71% of global revenues in 2025, equivalent to approximately USD 674.8 million. The clinical rationale is direct: vascular calcification incidence increases sharply with age, affecting an estimated 30 to 40% of adults over 65 and rising further in the presence of comorbidities such as diabetes mellitus, chronic kidney disease, and hypertension, all of which accelerate arterial calcium deposition. In the European real world IVL registry published in Heart (BMJ), the mean patient age across 454 treated cases was 73 years, with 75% of the cohort being male, a demographic profile consistent with the broader geriatric dominance of coronary IVL caseloads observed across high volume institutional settings.

In China, coronary calcification affects approximately 80% of adults aged 60 to 69, establishing the geriatric cohort as the single largest addressable patient group for IVL in the world's most populous market. The Shockwave C2+ Coronary IVL Catheter and M5+ Peripheral IVL Catheter are the primary platforms deployed in geriatric procedural settings, with their low pressure inflation profiles specifically suited to the more fragile vessel wall anatomy common in elderly patients. As the global population aged 65 and over continues to expand across North America, Europe, and Asia Pacific, the geriatric segment is structurally positioned to sustain its majority revenue contribution throughout the 2026 to 2035 forecast period.

Adult (18 to 64 Years)

The adult segment, comprising patients aged 18 to 64 years, accounts for 29.29% of IVL market revenues in 2025, approximately USD 279.5 million, and represents a growing share of the addressable population as calcified arterial disease increasingly manifests in younger age cohorts. The underlying driver is the rising global prevalence of metabolic syndrome, type 2 diabetes, and hypertension among working age adults, risk factors that accelerate coronary and peripheral calcification in patients as young as their forties. The LEAD FIM study conducted in China enrolled patients with a mean age of 64.1 years, a cohort straddling the adult and geriatric boundary, with 77 of 183 enrolled patients (41.9%) having diabetes, confirming the cardiometabolic comorbidity profile characteristic of earlier onset calcific disease.

Procedurally, adult patients with complex, multi vessel calcification are frequently candidates for IVL as an adjunct to drug eluting stent implantation, where optimal lesion preparation is critical to long term stent patency and reduced restenosis risk. As IVL expands into peripheral below the knee indications and renal artery interventions, anatomical territories where calcification can appear in younger patients with advanced metabolic disease, the adult segment is expected to grow proportionally faster than the geriatric segment over the 2026 to 2035 forecast period, incrementally shifting the age distribution of the overall IVL patient population.

By End Use

Hospitals

Hospitals account for the dominant share of IVL procedures, representing 72.2% of intravascular lithotripsy market revenues in 2025, approximately USD 688.5 million. The hospital segment's primacy reflects the capital equipment requirements of IVL deployment: the IVL generator is placed as an institutional asset within a dedicated cardiac catheterization laboratory or vascular surgery suite, and the per procedure catheter consumable is billed as part of an inpatient or outpatient hospital episode. In the United States, the establishment of dedicated MS DRG codes for coronary IVL in hospital inpatient settings effective October 1, 2023, and new HCPCS codes for hospital outpatient IVL in iliac, femoral, and popliteal artery indications effective January 1, 2024, have structured reimbursement squarely around the hospital setting, reinforcing institutional procurement as the primary commercial channel.

Academic medical centers and large health system networks, including high volume PCI programs at institutions that participated in the DISRUPT CAD III pivotal trial across 47 US and European sites, represent the core of the hospital user base, where IVL is embedded within formalized interventional cardiology protocols and supported by intravascular imaging programs. Germany's hospital based adoption trajectory is particularly instructive: from 2019 to 2023, the absolute volume of IVL procedures in planned PCI settings at German hospitals increased each year, with the 2021 DRG level reimbursement introduction using OPS Code 8-83d.6 serving as the primary institutional procurement catalyst, as confirmed by the peer reviewed analysis published in Clinical Research in Cardiology. The hospital segment is expected to retain majority status throughout the forecast period, underpinned by the procedural complexity of coronary IVL and the generator installation economics that favor centralized institutional settings over distributed ambulatory environments.

Ambulatory surgical centers

Ambulatory surgical centers (ASCs) represent 21.04% of IVL market revenues in 2025, approximately USD 200.8 million, and constitute the fastest growing end user segment as reimbursement frameworks increasingly accommodate outpatient delivery of interventional procedures. The 2024 CMS Outpatient Prospective Payment System Final Rule, effective January 1, 2024, introduced HCPCS codes for IVL in iliac, femoral, and popliteal artery indications within ambulatory payment classification structures, creating the reimbursement foundation for ASC adoption of peripheral IVL in the United States. ASC based IVL is concentrated in the peripheral arterial disease indication, where lower procedural complexity and shorter recovery times make the outpatient setting clinically appropriate for a meaningful share of PAD cases.

The Shockwave M5+ and L6 peripheral IVL catheters are the primary platforms deployed in ASC environments, with their compatibility with standard peripheral interventional equipment reducing the infrastructure investment required for ASC program initiation. The ongoing geographic expansion of IVL into above the knee and below the knee peripheral indications, combined with the entry of Boston Scientific's Bolt IVL system as a competing platform, is expected to broaden the case volume justification for ASC generator investment, accelerating this segment's growth relative to the hospital channel over the medium term.

Other end use

Other end use, encompassing specialty cardiovascular clinics, standalone cardiac catheterization laboratories, and academic and research institutions, account for 6.80% of market revenues in 2025, approximately USD 64.9 million. This segment is particularly relevant in Asia Pacific and Latin America, where standalone cardiac facilities and research affiliated catheterization centers represent an important access point for IVL in markets where large hospital infrastructure is geographically concentrated. In China, the SOLSTICE and LEAD FIM studies were conducted across multicenter research affiliated settings, reflecting the role of academic catheterization centers in driving early IVL adoption ahead of broader hospital network deployment. As reimbursement pathways mature in emerging markets and IVL platforms from domestic manufacturers such as MicroPort and Lepu Medical gain regulatory footholds, the others category is expected to grow in absolute terms, albeit more slowly than hospitals and ASCs, as volume migrates toward higher throughput institutional settings over the forecast horizon.

By Region

North America Intravascular Lithotripsy (IVL) Market

North America accounted for 41.6% of market revenues in 2025, approximately USD 397 million, representing the most commercially mature regional market by both absolute size and procedural penetration rate. The United States drives the majority of regional volume, underpinned by two transformative CMS coverage actions: the establishment of a New Technology Add-on Payment (NTAP) for coronary IVL effective October 1, 2021, and the creation of dedicated MS DRG codes for hospital inpatient coronary IVL procedures, effective October 1, 2023, described by industry observers as among the most consequential reimbursement coding updates for PCI procedures in decades.

The 2024 OPPS Final Rule further established new HCPCS codes for IVL performed in iliac, femoral, and popliteal artery indications in the outpatient hospital setting, effective January 1, 2024. Together, these coding frameworks materially reduced the financial exposure for health systems adopting IVL and were directly correlated with the acceleration of procedural volume observed in the Michigan based BMC2 registry, in which coronary IVL eventually exceeded the share of PCI procedures employing rotational atherectomy. In Canada, IVL adoption has progressed through select academic and high volume tertiary centers, with Canadian cardiovascular programs observing consistent replication of DISRUPT CAD III clinical outcomes in real world deployments. The combination of established reimbursement infrastructure, high PCI procedural volumes, and the entry of multiple competitive IVL platforms positions North America to sustain elevated growth rates through the forecast period, notwithstanding its status as the most commercially advanced regional market.

Europe Intravascular Lithotripsy (IVL) Market

Europe represented 27.67% of the market in 2025, approximately USD 264 million, with Germany, France, the United Kingdom, and Spain collectively accounting for the majority of regional procedural volume. Germany has emerged as the most analytically significant European market: an analysis published in Clinical Research in Cardiology confirmed that from 2019 to 2023, the absolute number of IVL procedures in planned PCI settings increased each year, while IVL's procedural share rose consistently relative to both rotational atherectomy and cutting/scoring balloon angioplasty, a structural reordering directly linked to the introduction of OPS Code 8-83d.6 in 2021 and subsequent DRG revisions. Under the 2024 German DRG framework, coronary IVL procedures under DRG F56B attract a reimbursement level of EUR 5,573.99, with DRG F19B covering more complex procedural combinations at EUR 7,576.44, uplifts of EUR 942 and EUR 941, respectively, versus 2025 comparators, creating positive reimbursement momentum for broader institutional uptake.

The European real world registry published in Heart (BMJ), covering 454 patients from seven centers across two European countries with a mean age of 73 years, documented device success of 98% and IVL related complication rates of only 1%, providing a substantial evidence base for guideline integration across major European cardiac societies. The United Kingdom's NICE technology appraisal pathway and France's HAS health technology assessment framework are both under active evaluation for IVL specific guidance, which, if issued favorably, would unlock broader adoption in these high volume markets. OECD analysis projects a 90% rise in CVD prevalence across EU member states between 2025 and 2050 as the share of adults aged 65 and over grows from 22% to 29%, a demographic trajectory that will sustain long run procedural volume growth independent of near term adoption dynamics.

Asia Pacific Intravascular Lithotripsy (IVL) Market

Asia Pacific represented 22.58% of IVL revenues in 2025, approximately USD 215.5 million, and is the fastest growing regional market, driven by converging forces across three distinct sub geographies. In China, Shockwave Medical and Genesis MedTech obtained domestic regulatory approval for the IVL system, enabling commercial distribution through China's provincial hospital network; the SOLSTICE trial, a prospective, single arm, multicenter study assessing IVL safety and effectiveness in Chinese patients with severely calcified coronary lesions, provided country specific evidence, while the LEAD FIM study at multiple Chinese centers further validated IVL in domestic PCI practice.

The Chinese Expert Consensus on the Diagnosis and Treatment of Calcific Coronary Lesions 2021 documented coronary calcification incidence of approximately 50% in adults aged 40 to 49 years, rising to approximately 80% in those aged 60 to 69, establishing the scale of the clinical opportunity in a population of over 1.4 billion. In Japan, the DISRUPT CAD IV study assessed coronary IVL safety and effectiveness specifically within a Japanese patient population, supporting regulatory alignment with the Pharmaceuticals and Medical Devices Agency (PMDA) and enabling commercialization across Japan's high volume catheterization laboratory network. In India, adoption remains at an earlier stage, but the directional shift is unambiguous: in conversations with six interventional cardiologists at leading cardiac centers in Mumbai, Delhi, and Chennai during our Q1 2026 expert panel, all participants confirmed that IVL was either in active use or formally under institutional evaluation, a material shift from 2023, when cost and limited reimbursement were cited as prohibitive barriers by the majority of the same clinical community.

Intravascular Lithotripsy (IVL) Market Share

The IVL industry is among the most concentrated device markets in interventional cardiology, with Shockwave Medical Inc., now wholly integrated into Johnson and Johnson MedTech, holding approximately 75% of global market revenues. This level of single company dominance, unusual for a medical device market of this size and age, reflects Shockwave's decade long first mover advantage in IVL, its comprehensive clinical evidence portfolio spanning DISRUPT CAD I through IV and DISRUPT PAD I through III, and its deeply embedded physician training ecosystem extending across more than 50 countries. The top five competitors, Shockwave (J&J), Boston Scientific, Abbott, Elixir Medical, and the Stryker/FastWave category, account for approximately 92% of global revenues, leaving an 8% share distributed across Philips, MicroPort, Lepu Medical, Cagent Vascular, and a small number of regional device suppliers.

At the segment level, Shockwave's coronary dominance is reinforced by the DISRUPT CAD Pooled analysis, currently the largest systematic assessment of coronary IVL outcomes based on individual patient data from DISRUPT CAD I through IV, which provides a published safety and efficacy record that no competitive coronary system yet matches in scale or follow up duration. The peripheral market is structurally more competitive: the DISRUPT PAD III randomized trial established 24 month outcome data for Shockwave's peripheral platform, but competing systems from Boston Scientific (Bolt, FDA cleared for above the knee peripheral disease in March 2025), Cagent Vascular (Serranator Sonic, first in human 2025), and Stryker/AVS (Pulse IVL) are entering the peripheral segment with differentiated technology propositions across energy modality, catheter design, and target vessel anatomy.

Boston Scientific's acquisition of Bolt Medical for up to approximately USD 664 million positions the company as the first credible large cap entrant to challenge Shockwave in the peripheral segment with an FDA cleared device, while the FRACTURE coronary IDE trial, commencing US enrollment in July 2025, signals Boston Scientific's intent to compete directly in the coronary indication over the medium term. Abbott's TECTONIC CAD IVL IDE study, a 335 patient, 47 site US pivotal trial initiated in March 2025 with an estimated completion date of June 2028, targets the same coronary calcification indication that currently represents Shockwave's highest volume revenue stream. The second order consequence of these competitive entries is an expected acceleration in hospital contract negotiations: as multi vendor IVL options become available, institutional buyer leverage is likely to increase, creating moderate per unit pricing pressure on the market leader even as overall procedural volumes expand.

From a geographic concentration standpoint, Shockwave's market share is highest in North America and Western Europe, markets where the platform benefits from the deepest reimbursement coverage and the most established physician familiarity. In emerging Asia Pacific markets, including China (where domestic IVL platforms from MicroPort and Lepu Medical are gaining regulatory and commercial footholds) and India (where adoption is at an earlier stage), Shockwave's dominance is less entrenched and competitive dynamics are likely to evolve differently than in mature markets over the forecast period.

M&A activity has been the defining competitive dynamic of the 2024 to 2025 period. Johnson and Johnson's USD 13.3 billion acquisition of Shockwave, Boston Scientific's USD 664 million acquisition of Bolt Medical, and Stryker's acquisition of Amplitude Vascular Systems have collectively committed in excess of USD 14 billion in capital to the IVL space over approximately 18 months, an investment intensity that underscores the market's strategic importance to the cardiovascular medtech industry.

Intravascular Lithotripsy (IVL) Market Companies

Major players operating in the intravascular lithotripsy (IVL) market are: Shockwave Medical Inc. (Johnson and Johnson), Boston Scientific, Abbott, Elixir Medical, FastWave Medical, Stryker (Amplitude Vascular Systems, Inc.), Philips, MicroPort, Lepu Medical, and Cagent Vascular.

Shockwave Medical Inc. (Johnson and Johnson MedTech) is the category pioneer and global market leader in IVL, having invented and commercialized the technology beginning in 2009. The company received FDA clearance for peripheral IVL in 2016 and FDA Pre Market Approval for coronary IVL in February 2021 under PMA P200039, following Breakthrough Device designation. Johnson and Johnson MedTech completed the acquisition of Shockwave Medical for approximately USD 13.3 billion in 2024, incorporating the full Shockwave catheter portfolio including the C2, C2+, M5+, L6, E8, and S4 IVL catheters, and Shockwave's global commercial and clinical infrastructure across 50+ countries.

The Shockwave Javelin Peripheral IVL Catheter, launched in the US in March 2025, introduced the first forward deployed IVL platform for treating sub total occlusions in extremely narrowed peripheral vessels, reporting 99% technical acute procedural success and a 1.1% major adverse event rate at 30 days. The COSIRA II clinical trial, evaluating IVL for refractory angina, is actively enrolling patients in the US, representing a potential expansion of the coronary indication set beyond current pre stenting vessel preparation.

Boston Scientific entered the IVL market formally through its January 2025 acquisition of Bolt Medical, in which it had maintained an approximately 26% strategic equity stake since Bolt's founding in 2019. The Bolt IVL system, subsequently FDA cleared on March 25, 2025, for above the knee peripheral arterial disease following the RESTORE ATK trial covering 97 subjects (completed July 2024), employs laser generated acoustic pressure waves for circumferential calcium fracture with enhanced deliverability in complex anatomies. The FRACTURE coronary IDE trial, commencing US enrollment in July 2025, will evaluate the Bolt coronary IVL system in PCI patients with severely calcified lesions, with an estimated completion timeline aligned to a potential coronary market entry in the latter half of the forecast period.

Abbott is advancing a coronary IVL program through the TECTONIC CAD IVL IDE study, a 335 patient, 47 site US pivotal trial initiated following FDA IDE approval on March 24, 2025. The Abbott Coronary IVL System uses high energy sound pressure waves to fracture calcium prior to stenting. Abbott's strategic commitment to IVL follows the less favorable outcome of its Diamondback 360 orbital atherectomy system in a 2024 pivotal trial, reinforcing the company's determination to maintain a competitive position in the calcified coronary lesion preparation segment, which represents a high growth sub market within its broader cardiovascular device portfolio.

Elixir Medical maintains a focused position in the IVL market, operating across coronary indications with a platform differentiated by its approach to calcification modification in complex lesion anatomies. The company's inclusion in the top five combined market share figure of approximately 92% reflects an established commercial and clinical presence in the coronary IVL segment.

FastWave Medical is a Minneapolis based, venture backed IVL developer with a dual platform strategy. The Artero electric IVL system, designed for peripheral arterial disease, completed its first in human study in 2024 with 100% procedural success and no adverse events at 30 days. The Sola laser IVL system, targeting coronary artery disease, received IRB approval for a coronary feasibility study in May 2025 and completed initial first in human procedures in June 2025. FastWave has raised over USD 40 million in total venture funding, with a USD 19 million oversubscribed round closing in December 2024, led by Epic Venture Partners.

Stryker (Amplitude Vascular Systems, Inc.) entered the intravascular lithotripsy market through its acquisition of Amplitude Vascular Systems, completed in 2025, following AVS's USD 36 million financing round in January 2025. AVS's Pulse IVL system, a peripheral electrohydraulic IVL platform, was the strategic rationale for Stryker's acquisition, which strengthens the company's Peripheral Vascular portfolio alongside its earlier acquisition of Inari Medical. The Pulse IVL system is progressing through clinical evaluation toward a future US regulatory submission.

Philips participates in the IVL ecosystem primarily through its intravascular imaging platforms including IVUS and optical coherence tomography (OCT), which are increasingly deployed in combination with IVL treatment to optimize calcium fracture confirmation and stent expansion. The European real world registry documented a significant increase in IVL use alongside intracoronary imaging over the study period, positioning Philips as an enabling platform beneficiary of IVL market growth.

MicroPort is one of China's leading cardiovascular device companies, with a broad interventional cardiology portfolio encompassing coronary stents, balloons, and guidewires. The company's participation in the intravascular lithotripsy market reflects its strategy of building a comprehensive interventional platform for the Chinese hospital system, where domestic regulatory approval for IVL was obtained through the Shockwave Medical and Genesis MedTech partnership, an ecosystem in which MicroPort's distribution capabilities are relevant.

Lepu Medical has developed an IVL Balloon Dilatation Catheter System and secured ANVISA regulatory approval for the Brazilian market, a milestone representing first mover access for a Chinese IVL manufacturer in a major Latin American market. Lepu's regulatory expansion strategy exemplifies the broader pattern of Chinese cardiovascular device companies commercializing IVL platforms in regulatory accessible emerging markets ahead of the more complex US and EU approval pathways.

Cagent Vascular is a Pennsylvania based developer of dual modality IVL technology. The Serranator Sonic IVL platform combines Cagent's proprietary serration remodeling therapy with a SONIC lithotripsy generator, a dual modality approach designed to address calcification in both femoropopliteal and infrapopliteal peripheral arteries more comprehensively than conventional single modality IVL. First in human REMODEL I cases were completed in 2025, with angiographic and IVUS imaging confirming successful calcium modification and lesion remodeling. A USD 41 million Series D round, co led by US Venture Partners and Astoria Health Investors, was secured to fund the REMODEL II pivotal trial and support commercial infrastructure development.

Intravascular Lithotripsy (IVL) Industry News

• Jul 2025: Boston Scientific commenced US enrollment in the FRACTURE investigational device exemption (IDE) trial, assessing the Bolt Medical laser IVL system for safety and efficacy in patients undergoing PCI for severely calcified coronary artery disease.
• Jun 2025: FastWave Medical announced the successful completion of initial first in human procedures in its feasibility study of Sola, its next generation coronary laser IVL system, with findings to inform US pivotal trial design and regulatory submission.
• May 2025: FastWave Medical received Institutional Review Board (IRB) approval to commence its coronary feasibility study of the Sola coronary laser IVL system, with FastWave partnering with Clinical Accelerator to advance toward a planned US pivotal trial.
• May 2025: Cagent Vascular completed first in human cases with its Serranator Sonic IVL system under the REMODEL I prospective study and simultaneously closed a USD 41 million oversubscribed Series D financing round, co led by US Venture Partners and Astoria Health Investors.
• Apr 2025: Stryker completed its acquisition of Amplitude Vascular Systems (AVS), formally entering the IVL market with the Pulse IVL platform for peripheral arterial disease.
• Mar 2025: Boston Scientific closed its acquisition of Bolt Medical; the Bolt IVL system received FDA clearance (letter dated March 25, 2025) for above the knee peripheral arterial disease based on RESTORE ATK trial data.
• Mar 2025: Abbott announced FDA approval of an investigational device exemption (IDE) for the TECTONIC CAD IVL clinical trial, enrolling up to 335 patients across 47 sites in the United States to evaluate the Abbott Coronary IVL System prior to stenting.
• Mar 2025: Shockwave Medical (Johnson and Johnson MedTech) launched the Shockwave Javelin Peripheral IVL Catheter in the US, the first forward deployed IVL platform for treating sub total occlusions and extremely narrowed peripheral vessels, reporting 99% technical acute procedural success and 1.1% major adverse events at 30 days.
• Jan 2025: Boston Scientific announced a definitive acquisition agreement with Bolt Medical, valued at up to approximately USD 664 million in upfront cash and potential future milestone payments, to acquire the remaining 74% stake in Bolt.
• Jan 2025: Amplitude Vascular Systems raised USD 36 million in financing to fund additional research into the safety and effectiveness of the Pulse IVL platform ahead of the Stryker acquisition.
• Dec 2024: FastWave Medical closed an oversubscribed USD 19 million funding round, led by Epic Venture Partners with participation from M&L Healthcare Investments, bringing total capital raised to over USD 40 million.
• Oct 2023: The Centers for Medicare and Medicaid Services (CMS) established new Medicare Severity Diagnosis Related Group (MS DRG) codes for coronary IVL hospital inpatient procedures, effective October 1, 2023, a landmark reimbursement milestone that materially reduced financial exposure for health systems adopting coronary IVL.

Market Concentration Score

The IVL market scores 9 out of 10 on the market concentration scale, reflecting the exceptional single firm dominance of Shockwave Medical (Johnson and Johnson MedTech) at approximately 75% global revenue share, compounded by a top five combined share of approximately 92%, a level of concentration characteristic of markets in early commercial maturity with strong first mover and clinical evidence advantages that competitors have not yet matched at scale.

The Intravascular Lithotripsy (IVL) market research report includes in-depth coverage of the industry with estimates & forecasts in terms of revenue (USD Million) from 2022 to 2035, for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Intravascular Lithotripsy Catheters and Balloons
  • Coronary IVL Balloons
  • Peripheral IVL Balloons
• IVL Generators / Consoles
• Accessories & Connector Cables

Market, By Application

• Coronary Artery Disease (CAD)
  • Calcified Coronary Lesions
  • Left Main Coronary Artery Disease
  • In-Stent Restenosis
• Peripheral Artery Disease (PAD)
  • Iliac Artery Lesions
  • Femoral-Popliteal Lesions
  • Infrapopliteal Lesions
• Other Vascular Applications

Market, By Age Group

• Adult (18–64 Years)
• Geriatric (65+ Years)

Market, By End Use

• Hospitals
• Ambulatory Surgical Centers
• Others

The above information is provided for the following regions and countries:

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Netherlands
  • Spain
  • Italy
• Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • Australia

• Middle East & Africa
  • Saudi Arabia
  • UAE
  • South Africa
• Latin America
  • Brazil
  • Mexico
  • Argentina